In short
Lacnotuzumab, also known as MCS110, is an investigational drug being studied in clinical trials for the treatment of various types of advanced cancer. This article provides an overview of the ongoing research, focusing on its safety, tolerability, and potential benefits for patients with advanced malignancies.
At a glance
- Drug Name
- Lacnotuzumab (MCS110)
- Drug Type
- Recombinant human monoclonal antibody
- Target
- Human macrophage colony-stimulating factor
- Condition Studied
- Different types of advanced cancer
- Administration
- Intravenous infusion
- Maximum Daily Dose
- 7.5 mg/kg
- Maximum Total Dose
- 1330 mg/kg
- Maximum Treatment Period
- 533 days
- Primary Objective
- Collect safety and tolerability data
- Secondary Objective
- Provide continued access to study treatment
What is Lacnotuzumab?
Lacnotuzumab, also known as MCS110, is an investigational drug being developed by Novartis Pharma AG for the treatment of advanced cancer. It is a type of medication called a monoclonal antibody, which is a laboratory-made protein that mimics the immune system's ability to fight off harmful cells in the body.
How Does Lacnotuzumab Work?
Lacnotuzumab is a recombinant human monoclonal antibody of the IgG1 kappa class. It works by targeting a specific protein in the body called human macrophage colony-stimulating factor. This protein plays a role in the growth and survival of certain types of cancer cells. By blocking this protein, lacnotuzumab may help slow down or stop the growth of cancer cells.
What Conditions Does Lacnotuzumab Treat?
Lacnotuzumab is being studied for the treatment of different types of advanced cancer. Advanced cancer refers to cancer that has spread from where it started to other parts of the body. This type of cancer is often more difficult to treat, which is why new medications like lacnotuzumab are being developed and tested.
Clinical Trials and Research
Lacnotuzumab is currently being studied in clinical trials. These trials are taking place in several European countries, including Belgium, France, Poland, Hungary, and the Czech Republic. The purpose of these trials is to evaluate the safety and effectiveness of lacnotuzumab in patients with advanced cancer.
One particular study is described as an "open-label, multi-center rollover protocol." This means that:
- Open-label: Both the researchers and participants know which treatment is being used.
- Multi-center: The study is being conducted at multiple hospitals or research centers.
- Rollover protocol: It allows patients who have participated in previous studies of lacnotuzumab to continue receiving the treatment if they are benefiting from it.
Administration and Dosage
Lacnotuzumab is administered as a concentrate for solution for infusion. This means it is given directly into the bloodstream through a vein (intravenously). The maximum daily dose being studied is 7.5 mg/kg (milligrams per kilogram of body weight). However, it's important to note that the optimal dosage is still being determined through clinical trials.
Potential Benefits and Safety
The main objective of the current clinical trials is to collect data on the safety and tolerability of lacnotuzumab, both when used alone and in combination with other cancer treatments. Researchers are particularly interested in:
- The frequency and nature of side effects (adverse events)
- How many patients need to have their dose interrupted or reduced
- How long patients are able to continue treatment
It's important to remember that lacnotuzumab is still an experimental treatment. While it shows promise, more research is needed to fully understand its benefits and risks. Patients interested in this treatment should discuss it with their healthcare provider and consider participating in clinical trials if appropriate.